Perspective Therapeutics (CATX) Equity Income (2023 - 2025)

Perspective Therapeutics has disclosed Equity Income across 3 years of filings, most recently posting -$1000.0 for Q4 2025.

• Equity Income for Q4 2025 came in at -$1000.0, up 50.0% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1000.0 (up 85.71% YoY), and the FY2025 annual result was -$2000.0, up 75.0% from the prior year.
• Equity Income came in at -$1000.0 for Q4 2025 at Perspective Therapeutics, roughly flat from -$1000.0 in the prior quarter.
• In the past five years, Equity Income ranged from a high of -$1000.0 in Q1 2025 to a low of -$12000.0 in Q3 2023.
• The 3-year median for Equity Income is -$2000.0 (2024), against an average of -$3857.1.
• Across the five-year window, Equity Income soared 60.0% in 2024 and jumped 50.0% in 2025, its largest moves.
• Perspective Therapeutics' Equity Income stood at -$5000.0 in 2023, then jumped by 60.0% to -$2000.0 in 2024, then surged by 50.0% to -$1000.0 in 2025.
• The last three Equity Income figures came in at -$1000.0 (Q4 2025), -$1000.0 (Q1 2025), and -$2000.0 (Q4 2024), per Business Quant data.